An exploratory analysis of neurocognition in methamphetamine-induced psychotic disorder and paranoid schizophrenia

Cognitive and Behavioral Neurology

Volumn 21, Issue 2, 2008, Pages 98-103

  Jacobs, Elizabeth ^a   Fujii, Daryl ^a   Schiffman, Jason ^a   Bello, Iruma ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Methamphetamine induced psychotic disorder; Neurocognition; Psychosis; Schizophrenia

Indexed keywords

METHAMPHETAMINE; CENTRAL STIMULANT AGENT;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; EXPLORATORY RESEARCH; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PARANOID SCHIZOPHRENIA; PATIENT SELECTION; PERFORMANCE; PRIORITY JOURNAL; PSYCHOSIS; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; DIFFERENTIAL DIAGNOSIS; DRUG ABUSE; FEMALE; MALE; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; REPRODUCIBILITY; STATISTICS;

ADULT; AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; METHAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; PSYCHOMETRICS; PSYCHOSES, SUBSTANCE-INDUCED; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA, PARANOID;

EID: 49849097843     PISSN: 15433633     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNN.0b013e31816bdf90     Document Type: Article

References (27)

1. Baumeister AA, Francis JL. Historical development of the dopamine model of schizophrenia. J Hist Neurosci. 2002;11: 265-277.
2. Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull. 1992;18:115-122.
3. Boutros NN, Bowers MB. Chronic substance-induced psychotic disorders: state of the literature. J Neuropsychiatry Clin Neurosci. 1996;8:262-269.
4. Caton CLM, Drake RE, Hasin DS, et al. Differences between early- phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch Gen Psychiatry.2005;62: 137-145.
5. National Drug Intelligence Center: National Drug Assessment Report (DOJ Product No. 2005-Q0317-005). Washington, DC: Government Printing Office; 2005.
6. Zweben JE, Cohen JB, Christian D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13:181-190.
7. Hill SK, Keshavan MS, Thase ME, et al. Neurocognitive dysfunction in antipsychotic-naive first-episode unipolar psychotic depression. Am J Psychiatry. 2004;161:996-1003.
8. Evans JD, Heaton RK, Paulsen JS, et al. Schizoaffective disorder: a form of schizophrenia or affective disorder? J Clin Psychiatry.1999;60:874- 882.
9. Heinrichs R, Zakzanis K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12: 426-445.
10. Flashman L, Green M. Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment. Psychiatr Clin North Am. 2004;27:1-18.
11. Green M. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
12. Green M, Kern R, Heaton R. Longitudinal studies of cognition and functional outcomes in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41-51.
13. Jacobs E, Haning W III. Methamphetamine. In: Fujii D, Ahmed I, eds. Spectrum of Psychotic Disorders: Neurobiology, Etiology, and Pathogenesis. Cambridge: Cambridge University Press; 2007: 382-405.
14. Kalechstein AD, Newton TF, Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci. 2003; 15:215-220.
15. Simon SL, Dormier C, Carnell J, et al. Cognitive impairment in individuals currently using methamphetamine. Am J Addict. 2000; 9:222-231.
16. Salo R, Nordahl TE, Possin K, et al. Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatr Res. 2002;111:65-74.
17. Sim T, Simon SL, Domier CP, et al. Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology. J Addict Dis. 2002;21:75-89.
18. Rippeth JD, Heaton RK, Carey CL, et al. Methamphetamine dependence increases risk of neurocognitive impairment in HIV infected persons. J Int Neuropsychol Soc. 2004;10:1-14.
19. Gonzalez R, Rippeth JD, Carey CL, et al. Neuroco- gnitive performance of methamphetamine users discordant for history of marijuana exposure. Drug Alcohol Depend.2004;76: 181-190.
20. Grant I, Gonzalez R, Carey C, et al. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc. 2003;9:679-689.
21. Wechsler D. Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: Psychological Corporation; 1999.
22. Gold JM, Queern C, Iannone VN, et al. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, I: sensitivity, reliability, and validity. Am J Psychiatry. 1999;156:1944-1950.
23. Homack S, Lee D, Riccio CA. Test review: Delis-Kaplan executive function system. J Clin Exp Neuropsychol. 2004;27:599-609.
24. Cicerone KD. Clinical sensitivity of four measures of attention to mild traumatic brain injury. Clinical Neuropsychol.1997;11:266-272.
25. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. New York: Oxford University Press; 1998.
26. Marcopulos BA, Fujii D, O'Grady J, et al. Providing neuropsycho- logical services for persons with schizophrenia: a review of the literature and prescription for practice. In: Morgan J, Ricker J, eds. Textbook of Clinical Neuropsychology. London: Psychology Press. 2008:743-761.
27. Fujii DE, Ahmed I. Is psychosis a neurobiological syndrome? Can J Psychiatry. 2004;49:713-718.